Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update

Posted by Defense World Staff on Apr 3rd, 2025

Tharimmune, Inc. (NASDAQ:THAR – Get Free Report) was the target of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 30,200 shares, a decline of 16.8% from the February 28th total of 36,300 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average daily trading volume, of 64,800 shares, the days-to-cover ratio is presently 0.5 days.

Wall Street Analyst Weigh In

Several research analysts have issued reports on THAR shares. RODMAN&RENSHAW raised shares of Tharimmune to a “strong-buy” rating in a report on Friday, December 6th. Rodman & Renshaw initiated coverage on shares of Tharimmune in a report on Friday, December 6th. They issued a “buy” rating and a $17.00 price objective for the company.

Read Our Latest Analysis on THAR

Tharimmune Price Performance

Shares of THAR opened at $1.29 on Thursday. The firm has a market capitalization of $2.72 million, a P/E ratio of -0.13 and a beta of 1.17. Tharimmune has a one year low of $1.20 and a one year high of $7.13. The business has a fifty day moving average of $1.68 and a 200 day moving average of $2.06.

Tharimmune (NASDAQ:THAR – Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($2.02) earnings per share for the quarter.

Institutional Investors Weigh In On Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Virtu Financial LLC acquired a new position in Tharimmune, Inc. (NASDAQ:THAR – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned 1.11% of Tharimmune as of its most recent SEC filing. Institutional investors own 1.16% of the company’s stock.

About Tharimmune

(Get Free Report)

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).